Dominik Hlauschek

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Cristina Saura, Dominik Hlauschek, Mafalda Oliveira et al. · The Lancet Oncology · 2019 · 95 citations

Breast Oncology, Endocrine-related Cancer, Taselisib Versus +11

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone

Ivana Šestak, Miguel Martín, Peter Dubsky et al. · Breast Cancer Research and Treatment · 2019 · 86 citations · Full text

Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2− Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only

Martin Filipits, Peter Dubsky, Margaretha Rudas et al. · Clinical Cancer Research · 2019 · 73 citations · Full text

Randomized clinical trial of the effect of a fibrin sealant patch on pancreatic fistula formation after pancreatoduodenectomy

Martin Schindl, R. Függer, P. Götzinger et al. · British journal of surgery · 2018 · 42 citations · Full text

Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial

Georg Pfeiler, Dominik Hlauschek, Erica L. Mayer et al. · Journal of Clinical Oncology · 2023 · 33 citations